Study Selection The trials we included met the following criteria: (1) RCTs that compared GLP-1 receptor agonist with a placebo or active control (other antidiabetic drugs or insulin), (2) patients with type 2 diabetes, type 1 diabetes, prediabetes, overweight or obesity, (3) with durations of at least 24 weeks, and (4) reported the occurrence of at least one case of various thyroid disorders as adverse events
Based on reported changes in diet and food spending among GLP-1 users, Roe (2025) attempts to quantify what this could mean for the food system
INFORMATION What is Retatrutide (60 mg)
doi: 10.1111/j.1432-1033.1984.tb08595.x 18 JrnvallHCarlquistMKwaukSOtteSCMcIntoshCHBrownJCet al
Possible concerns may include nausea, vomiting, diarrhea, constipation, appetite suppression, dehydration, fatigue, gallbladder concerns, blood sugar changes, excessive weight loss, and loss of lean muscle if weight drops too quickly
Protein : Dietary protein, especially plant-based protein, may increase GLP-1 secretion and prolong satiety signals